The Effects of SGLT Inhibition on Diabetic Cardiomyopathy
The clinical trial, sponsored by The University of Hong Kong, investigates the effects of SGLT2 inhibition on diabetic cardiomyopathy, a condition with significant morbidity and mortality among patients with type 2 diabetes. The study aims to elucidate the mechanistic insights of dapagliflozin, an SGLT2 inhibitor, on cardiovascular outcomes beyond glycemic control. Given the increasing prevalence of diabetes and associated cardiovascular complications, successful outcomes could enhance dapagliflozin's market positioning against competitors in the SGLT2 inhibitor space, such as empagliflozin and canagliflozin. The findings may also support expanded indications for SGLT2 inhibitors, potentially leading to new revenue streams and increased market share. Investors should monitor the trial's progress and results for implications on market dynamics and competitive landscape.
Indication: Type2 Diabetes
Modality: small molecule
Target: SGLT2 (Sodium-Glucose Cotransporter 2)
Sponsor: The University of Hong Kong
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 03, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: SGLT2 (Sodium-Glucose Cotransporter 2)
View original source fields
Condition raw: Type2 Diabetes, Heart Failure With Reduced Ejection Fraction
Condition normalized: Type2 Diabetes, Heart Failure With Reduced Ejection Fraction
Modality raw: small molecule
Modality normalized: small molecule
Target raw: SGLT2 (Sodium-Glucose Cotransporter 2)
Target normalized: SGLT2 (Sodium-Glucose Cotransporter 2)